Newest Approach to Breast Cancer
Emerging Issues with Adaptation of Clinical Trial Design in Drug Development* H.M. James Hung Division of Biometrics I, Office of Biostatistics, OPaSS,
Biomarkers and Surrogate Endpoints in Drug Development Technical and Regulatory Considerations Biomarkers and Surrogate Endpoints in Drug Development Technical.
Surrogate Endpoints: A Regulatory View Greg Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health Food and Drug.
Oncologists Views about the Treatments and Care Associated with Advanced varian Cancer Jenkins V 1, Banerjee S 2, Ledermann J 3, Gore M 2, Catt S 1, Monson.
CRITICAL APPRAISAL ON AN ARTICLE ABOUT PROGNOSIS post.
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone.
SUTENT® (sunitinib malate) Slide Kit
Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis
Maintenance Therapy In Multiple Myeloma
Late Outcomes of Cord Blood Transplantation for Patients with Hurler Syndrome
EpiCept Corporation (EPCT)
